Skip to content

Using GLP-1s

Oral semaglutide

Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.

By the glp1.how editorial teamReviewed

Oral semaglutide is the same GLP-1 medication found in Ozempic and Wegovy, made into a daily tablet. Because semaglutide is a peptide that stomach acid and enzymes normally break down, the tablet includes an absorption enhancer (SNAC) that helps a small fraction of the dose get into the bloodstream through the stomach wall. That's why oral doses are much larger in milligrams than injected ones, and why the timing rules are strict: take it on an empty stomach in the morning with up to 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other oral medicines. Check your own label for the exact instructions.

In the US it is sold for two uses. Rybelsus was approved in 2019 for type 2 diabetes. A reformulated version, Ozempic tablets, had its US launch announced for May 4, 2026 (external link), and one US label now covers both products. The Ozempic 1.5 mg starting tablet takes the place of Rybelsus 3 mg, and the 4 mg and 9 mg tablets match Rybelsus 7 mg and 14 mg. The strengths aren't interchangeable mg-for-mg, and the label only allows switching between the two after the first 30 days.

The Wegovy pill (oral semaglutide 25 mg) was approved on December 22, 2025 (external link) as the first oral GLP-1 for chronic weight management. In the OASIS 4 trial (external link), people taking it lost an average of 13.6% of their body weight at 64 weeks, compared with 2.2% on placebo. OASIS 4 had no injection arm. A Novo Nordisk-funded indirect comparison (external link) against the STEP 1 trial of injectable Wegovy 2.4 mg found weight loss comparable to the injection. See comparing the GLP-1 pills, the history of GLP-1 medications and manufacturer savings cards.

Both labels give the same water and timing rule: the Rybelsus and Ozempic tablets label (external link) and the Wegovy prescribing information (external link), which also lists salcaprozate sodium (SNAC) among the tablet's ingredients.

oral-semaglutidesemaglutiderybelsuswegovyoral-glp1glossary

Revision history

Updated 8 times since Sep 26, 2026 · show changes
  1. v9

    Summary rewritten; Body revised; Metadata updated

  2. v8

    Body revised

  3. v7

    Body revised

  4. v6

    Body revised

  5. v5

    Body revised

  6. v4

    Summary rewritten; Metadata updated

  7. v3

    Summary rewritten; Body revised; Metadata updated

  8. v2

    Published

  9. v1

    First version

Related guides

  • Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo · There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.
  • Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration · Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
  • Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found · If you've lost weight on Zepbound or Wegovy and want off the weekly injection, can a daily pill hold your results? One randomized trial has now tested exactly that, and Wegovy users also have an on-label switch to Wegovy tablets. This guide covers what the trial found, how much weight people kept, what the switch felt like, and the big question the trial didn't answer.
  • GLP-1 myths vs. facts: what the media and social feeds get wrong · A plain-language, evidence-checked look at the most common claims about GLP-1 medications in the news and on social media: which are false, which are true, and which are still unsettled, with the studies behind each verdict.
  • Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found · STEP 1, SURMOUNT-4, SELECT, LEADER: GLP-1 trial names get quoted everywhere, usually without context. This reference page lists 205 named, completed GLP-1 trials in one place, grouped by drug and by question, with what each one tested, who sponsored it, its headline result, and a link to the published paper. It also lists the trials that finished but have not reported, and shows who paid for the research.
  • Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show · Some people space their weekly GLP-1 to every 10 or 14 days to save money or ease off. This guide covers what that does to drug levels, what the two small studies found, why that isn't proof yet, and the risks worth planning around with a prescriber.

Related terms

  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Peptide · A short chain of amino acids: the molecular structure of the natural hormones GLP-1 medications mimic, and of most of the medications themselves.
  • Ozempic · Novo Nordisk's brand name for semaglutide for type 2 diabetes, sold as a weekly injection and, since May 2026 in the US, as daily Ozempic tablets.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Wegovy · Novo Nordisk's brand name for semaglutide (weekly injection or, since December 2025, a daily pill), FDA-approved for chronic weight management and heart-risk reduction, and as an injection for MASH liver disease.
  • Novo Nordisk · A Danish pharmaceutical company that makes semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), among other medications.

Was this helpful?

Improve this page